Who we are
SemaglutideGLPOne.com publishes editorial reviews and rankings of semaglutide telehealth providers in the United States. The editorial team is led by Dr. Sam Saberian (Lead Medical Researcher) with editorial review by Julliana Edwards (Editor). Every provider is scored against the published v3.0 six-pillar transparency rubric, applied uniformly. Rankings are based on the methodology, and providers cannot pay to appear higher in organic comparisons.
Dr. Sam Saberian — Lead Medical Researcher
Dr. Sam Saberian leads medical research for SemaglutideGLPOne.com. Areas of focus: GLP-1 receptor agonist therapeutics, peptide pharmacology, and telehealth pharmacy traceability standards. Lead author of the v3.0 six-pillar transparency rubric.
Julliana Edwards — Editor
Julliana Edwards is the editor for SemaglutideGLPOne.com. Reviews and edits all editorial content for accuracy, clarity, and adherence to the published rubric methodology before publication. Leads the corrections process and quarterly methodology review.
Our scope
This site exclusively covers semaglutide and the broader GLP-1 / GIP therapeutic class. We cover:
- Semaglutide brand-name products: Ozempic, Wegovy, Rybelsus (all manufactured by Novo Nordisk)
- Compounded semaglutide dispensed via 503A and 503B pharmacies
- Comparator GLP-1 / GIP medications: tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity)
- 10 U.S. semaglutide telehealth providers, scored against the v3.0 six-pillar transparency rubric
- FDA approvals, label expansions, and regulatory actions affecting the class
Why we exist — our editorial mission
The semaglutide telehealth landscape is fragmented and opaque. Patients face wide pricing variation ($99-$1,349/mo), inconsistent pharmacy disclosure, and unclear medical oversight. SemaglutideGLPOne.com's mission is to provide patients with clear, sourced answers to a question existing review sites don't answer well: which semaglutide telehealth provider is actually right for me?
What this site is not
- Not a healthcare provider. We do not employ physicians, prescribe medications, or operate a pharmacy.
- Not a pharmacy or insurance broker.
- Not a substitute for medical advice. Information is educational.
- Not affiliated with the FDA, FTC, Novo Nordisk, Eli Lilly, or any government agency.
Contact & corrections
For corrections, provider-data updates, or to suggest a provider for review, email semaglutideglpone@gmail.com. We respond to documented corrections within 72 hours.